Jump to section
IdentificationPharmacologyInteractionsReferencesTrialsEconomicsPropertiesSpectraTaxonomyClocortolone
Identification
- Name
- Clocortolone
- Accession Number
- DB00838 (APRD00877)
- Type
- Small Molecule
- Groups
- Approved
- Description
Clocortolone is a medium potency corticosteroid that is often used as a topical cream for the relief of inflammatory oand pruritic (itching) arising from steroid-responsive dermatoses of the scalp.
- Structure
Structure for DB00838 (Clocortolone)
- Synonyms
- 9-chloro-6alpha-Fluoro-11beta,21-dihydroxy-16alpha-methyl-1,4-pregnadien-3,20-dione
- 9-chloro-6alpha-Fluoro-16alpha-methyl-1,4-pregnadiene-11beta,21-diol-3,20-dione
- Clocortolon
- Clocortolona
- Clocortolone
- Clocortolonum
- External IDs
- SH 863
- Product Ingredients
Ingredient UNII CAS InChI Key Clocortolone acetate 85061HTR8T 4258-85-9 ARPLCFGLEYFDCN-CDACMRRYSA-N Clocortolone caproate 871M9PSU7T 4891-71-8 MMTRTBFDFNRBQO-ANHDKODLSA-N Clocortolone pivalate QBL8IZH14X 34097-16-0 SXYZQZLHAIHKKY-GSTUPEFVSA-N - Prescription Products
Name Dosage Strength Route Labeller Marketing Start Marketing End Cloderm Cream .001 g/g Topical Coria Laboratories 1977-08-22 2016-05-01 US 
Cloderm Cream .001 g/g Topical Promius Pharma, LLC 1977-08-22 Not applicable US - Generic Prescription Products
Name Dosage Strength Route Labeller Marketing Start Marketing End Clocortolone Pivalate Cream .001 g/g Topical Dr Reddy's Laboratories 2014-02-17 Not applicable US - Categories
- Adrenal Cortex Hormones
- Anti-Inflammatory Agents
- Corticosteroids, Dermatological Preparations
- Corticosteroids, Moderately Potent (Group II)
- Corticosteroids, Plain
- Dermatologicals
- Glucocorticoids
- Hormones
- Hormones, Hormone Substitutes, and Hormone Antagonists
- Pregnadienediols
- Pregnadienes
- Pregnanes
- Steroids
- Steroids, Fluorinated
- UNII
- N8ZUB7XE0H
- CAS number
- 4828-27-7
- Weight
- Average: 410.907
Monoisotopic: 410.166015296 - Chemical Formula
- C22H28ClFO4
- InChI Key
- YMTMADLUXIRMGX-RFPWEZLHSA-N
- InChI
- InChI=1S/C22H28ClFO4/c1-11-6-13-14-8-16(24)15-7-12(26)4-5-21(15,3)22(14,23)18(28)9-20(13,2)19(11)17(27)10-25/h4-5,7,11,13-14,16,18-19,25,28H,6,8-10H2,1-3H3/t11-,13+,14+,16+,18+,19-,20+,21+,22+/m1/s1
- IUPAC Name
- (1R,2S,8S,10S,11S,13R,14S,15S,17S)-1-chloro-8-fluoro-17-hydroxy-14-(2-hydroxyacetyl)-2,13,15-trimethyltetracyclo[8.7.0.0²,⁷.0¹¹,¹⁵]heptadeca-3,6-dien-5-one
- SMILES
- [H][C@@]12C[C@@H](C)[C@H](C(=O)CO)[C@@]1(C)C[C@H](O)[C@@]1(Cl)[C@@]2([H])C[C@H](F)C2=CC(=O)C=C[C@]12C
Pharmacology
- Indication
For short-term topical treatment of the inflammatory and pruritic manifestations of moderate to severe corticosteroid-responsive dermatoses of the scalp.
- Structured Indications
- Pharmacodynamics
Like other topical corticosteroids, clocortolone has anti-inflammatory, antipruritic, and vasoconstrictive properties. Once absorbed through the skin, topical corticosteroids are handled through pharmacokinetic pathways similar to systemically administered corticosteroids. Clocortolone is a moderate potency topical corticosteroid that should not be used with occlusive dressings. It is recommended that treatment should be limited to 2 consecutive weeks and therapy should be discontinued when adequate results have been achieved.
- Mechanism of action
The precise mechanism of the antiinflammatory activity of topical steroids in the treatment of steroid-responsive dermatoses, in general, is uncertain. However, corticosteroids are thought to act by the induction of phospholipase A2 inhibitory proteins, collectively called lipocortins. It is postulated that these proteins control the biosynthesis of potent mediators of inflammation such as prostaglandins and leukotrienes by inhibiting the release of their common precursor arachidonic acid. Arachidonic acid is released from membrane phospholipids by phospholipase A2. These enzyme transcriptional changes are mediated by the drug binding first to the glucocorticoid receptor. This complex can migrate to the cell nucleus which then binds to DNA initiating genetic activation and repression of various genes.
Target Actions Organism AGlucocorticoid receptor agonistHuman - Absorption
Topical corticosteroids can be absorbed from intact healthy skin. The extent of percutaneous absorption of topical corticosteroids is determined by many factors, including the vehicle and the integrity of the epidermal barrier. Occlusion, inflammation and/or other disease processes in the skin may also increase percutaneous absorption.
- Volume of distribution
- Not Available
- Protein binding
- Not Available
- Metabolism
Metabolized, primarily in the liver, and then excreted by the kidneys.
- Route of elimination
- Not Available
- Half life
- Not Available
- Clearance
- Not Available
- Toxicity
Topically applied clocortolone can be absorbed in sufficient amounts to produce systemic effects. Symptoms of overdose include thinning of skin and suppression of adrenal cortex (decreased ability to respond to stress).
- Affected organisms
- Humans and other mammals
- Pathways
- Not Available
- Pharmacogenomic Effects/ADRs
- Not Available
Interactions
- Drug Interactions
Drug Interaction Drug group (4R)-limonene The risk or severity of adverse effects can be increased when (4R)-limonene is combined with Clocortolone. Investigational 1,10-Phenanthroline The risk or severity of adverse effects can be increased when Clocortolone is combined with 1,10-Phenanthroline. Experimental Aceclofenac The risk or severity of adverse effects can be increased when Aceclofenac is combined with Clocortolone. Approved, Investigational Acemetacin The risk or severity of adverse effects can be increased when Acemetacin is combined with Clocortolone. Approved, Experimental, Investigational Acetylsalicylic acid The risk or severity of adverse effects can be increased when Acetylsalicylic acid is combined with Clocortolone. Approved, Vet Approved Adapalene The risk or severity of adverse effects can be increased when Adapalene is combined with Clocortolone. Approved Alclofenac The risk or severity of adverse effects can be increased when Alclofenac is combined with Clocortolone. Approved, Withdrawn Aldesleukin Clocortolone may decrease the antineoplastic activities of Aldesleukin. Approved Almasilate The bioavailability of Clocortolone can be decreased when combined with Almasilate. Approved, Experimental Alminoprofen The risk or severity of adverse effects can be increased when Alminoprofen is combined with Clocortolone. Experimental Aloglutamol The bioavailability of Clocortolone can be decreased when combined with Aloglutamol. Approved Aloxiprin The risk or severity of adverse effects can be increased when Aloxiprin is combined with Clocortolone. Experimental Aluminium The bioavailability of Clocortolone can be decreased when combined with Aluminium. Approved, Investigational Aluminium acetoacetate The bioavailability of Clocortolone can be decreased when combined with Aluminium acetoacetate. Experimental Aluminium glycinate The bioavailability of Clocortolone can be decreased when combined with Aluminium glycinate. Experimental Aluminum hydroxide The bioavailability of Clocortolone can be decreased when combined with Aluminum hydroxide. Approved, Investigational Ambenonium The risk or severity of adverse effects can be increased when Clocortolone is combined with Ambenonium. Approved Aminosalicylic Acid The risk or severity of adverse effects can be increased when Aminosalicylic Acid is combined with Clocortolone. Approved Amiodarone The serum concentration of Clocortolone can be increased when it is combined with Amiodarone. Approved, Investigational Amphotericin B Clocortolone may increase the hypokalemic activities of Amphotericin B. Approved, Investigational Andrographolide The risk or severity of adverse effects can be increased when Andrographolide is combined with Clocortolone. Investigational Anisodamine The risk or severity of adverse effects can be increased when Anisodamine is combined with Clocortolone. Investigational Anthrax immune globulin human The risk or severity of adverse effects can be increased when Clocortolone is combined with Anthrax immune globulin human. Approved Antipyrine The risk or severity of adverse effects can be increased when Antipyrine is combined with Clocortolone. Approved, Investigational Apalutamide The serum concentration of Clocortolone can be decreased when it is combined with Apalutamide. Approved, Investigational Apocynin The risk or severity of adverse effects can be increased when Apocynin is combined with Clocortolone. Investigational Apremilast The risk or severity of adverse effects can be increased when Apremilast is combined with Clocortolone. Approved, Investigational Aprepitant The serum concentration of Clocortolone can be increased when it is combined with Aprepitant. Approved, Investigational Atazanavir The serum concentration of Clocortolone can be increased when it is combined with Atazanavir. Approved, Investigational Atracurium besylate Atracurium besylate may increase the adverse neuromuscular activities of Clocortolone. Approved Azapropazone The risk or severity of adverse effects can be increased when Azapropazone is combined with Clocortolone. Withdrawn Azelastine The risk or severity of adverse effects can be increased when Azelastine is combined with Clocortolone. Approved Azosemide Clocortolone may increase the hypokalemic activities of Azosemide. Investigational Bacillus calmette-guerin substrain connaught live antigen The risk or severity of adverse effects can be increased when Clocortolone is combined with Bacillus calmette-guerin substrain connaught live antigen. Approved, Investigational Bacillus calmette-guerin substrain tice live antigen The risk or severity of adverse effects can be increased when Clocortolone is combined with Bacillus calmette-guerin substrain tice live antigen. Approved Balsalazide The risk or severity of adverse effects can be increased when Balsalazide is combined with Clocortolone. Approved, Investigational BCG vaccine The risk or severity of adverse effects can be increased when Clocortolone is combined with BCG vaccine. Investigational Bendazac The risk or severity of adverse effects can be increased when Bendazac is combined with Clocortolone. Experimental Bendroflumethiazide Clocortolone may increase the hypokalemic activities of Bendroflumethiazide. Approved Benorilate The risk or severity of adverse effects can be increased when Benorilate is combined with Clocortolone. Experimental Benoxaprofen The risk or severity of adverse effects can be increased when Benoxaprofen is combined with Clocortolone. Withdrawn Benzoic Acid The therapeutic efficacy of Benzoic Acid can be decreased when used in combination with Clocortolone. Approved, Investigational Benzydamine The risk or severity of adverse effects can be increased when Benzydamine is combined with Clocortolone. Approved Bevonium The risk or severity of adverse effects can be increased when Bevonium is combined with Clocortolone. Experimental Bismuth Subcitrate The bioavailability of Clocortolone can be decreased when combined with Bismuth Subcitrate. Approved, Investigational Bismuth subnitrate The bioavailability of Clocortolone can be decreased when combined with Bismuth subnitrate. Approved Boceprevir The serum concentration of Clocortolone can be increased when it is combined with Boceprevir. Approved, Withdrawn Bromfenac The risk or severity of adverse effects can be increased when Bromfenac is combined with Clocortolone. Approved Bucillamine The risk or severity of adverse effects can be increased when Bucillamine is combined with Clocortolone. Investigational Bufexamac The risk or severity of adverse effects can be increased when Bufexamac is combined with Clocortolone. Approved, Experimental Bumadizone The risk or severity of adverse effects can be increased when Bumadizone is combined with Clocortolone. Experimental Bumetanide Clocortolone may increase the hypokalemic activities of Bumetanide. Approved Calcitriol The therapeutic efficacy of Calcitriol can be decreased when used in combination with Clocortolone. Approved, Nutraceutical Calcium Carbonate The bioavailability of Clocortolone can be decreased when combined with Calcium Carbonate. Approved, Investigational Calcium silicate The bioavailability of Clocortolone can be decreased when combined with Calcium silicate. Experimental Capromab pendetide Clocortolone may decrease effectiveness of Capromab pendetide as a diagnostic agent. Approved Carbamazepine The serum concentration of Clocortolone can be decreased when it is combined with Carbamazepine. Approved, Investigational Carbaspirin calcium The risk or severity of adverse effects can be increased when Carbaspirin calcium is combined with Clocortolone. Experimental, Investigational Carprofen The risk or severity of adverse effects can be increased when Carprofen is combined with Clocortolone. Approved, Vet Approved, Withdrawn Castanospermine The risk or severity of adverse effects can be increased when Castanospermine is combined with Clocortolone. Experimental Celecoxib The risk or severity of adverse effects can be increased when Celecoxib is combined with Clocortolone. Approved, Investigational Ceritinib Clocortolone may increase the hyperglycemic activities of Ceritinib. Approved Chloroquine The risk or severity of adverse effects can be increased when Chloroquine is combined with Clocortolone. Approved, Investigational, Vet Approved Chlorothiazide Clocortolone may increase the hypokalemic activities of Chlorothiazide. Approved, Vet Approved Chlorotrianisene The serum concentration of Clocortolone can be increased when it is combined with Chlorotrianisene. Investigational, Withdrawn Chlorthalidone Clocortolone may increase the hypokalemic activities of Chlorthalidone. Approved Cholestyramine Cholestyramine can cause a decrease in the absorption of Clocortolone resulting in a reduced serum concentration and potentially a decrease in efficacy. Approved, Investigational Choline magnesium trisalicylate The risk or severity of adverse effects can be increased when Choline magnesium trisalicylate is combined with Clocortolone. Approved Cinoxacin The risk or severity of adverse effects can be increased when Clocortolone is combined with Cinoxacin. Approved, Investigational, Withdrawn Clarithromycin The serum concentration of Clocortolone can be increased when it is combined with Clarithromycin. Approved Clonixin The risk or severity of adverse effects can be increased when Clonixin is combined with Clocortolone. Approved Clostridium tetani toxoid antigen (formaldehyde inactivated) The risk or severity of adverse effects can be increased when Clocortolone is combined with Clostridium tetani toxoid antigen (formaldehyde inactivated). Approved Cobicistat The serum concentration of Clocortolone can be increased when it is combined with Cobicistat. Approved Colesevelam Colesevelam can cause a decrease in the absorption of Clocortolone resulting in a reduced serum concentration and potentially a decrease in efficacy. Approved Colestipol Colestipol can cause a decrease in the absorption of Clocortolone resulting in a reduced serum concentration and potentially a decrease in efficacy. Approved Conjugated estrogens The serum concentration of Clocortolone can be increased when it is combined with Conjugated estrogens. Approved Corticorelin ovine triflutate The therapeutic efficacy of Corticorelin ovine triflutate can be decreased when used in combination with Clocortolone. Approved Corynebacterium diphtheriae toxoid antigen (formaldehyde inactivated) The risk or severity of adverse effects can be increased when Clocortolone is combined with Corynebacterium diphtheriae toxoid antigen (formaldehyde inactivated). Approved Coumaphos The risk or severity of adverse effects can be increased when Clocortolone is combined with Coumaphos. Vet Approved Curcumin The risk or severity of adverse effects can be increased when Curcumin is combined with Clocortolone. Approved, Investigational Cyclopenthiazide Clocortolone may increase the hypokalemic activities of Cyclopenthiazide. Experimental Daidzein The serum concentration of Clocortolone can be increased when it is combined with Daidzein. Experimental Danazol Clocortolone may increase the fluid retaining activities of Danazol. Approved Darunavir The serum concentration of Clocortolone can be increased when it is combined with Darunavir. Approved Decamethonium The risk or severity of adverse effects can be increased when Clocortolone is combined with Decamethonium. Approved Deferasirox The risk or severity of adverse effects can be increased when Clocortolone is combined with Deferasirox. Approved, Investigational Demecarium The risk or severity of adverse effects can be increased when Clocortolone is combined with Demecarium. Approved Dersalazine The risk or severity of adverse effects can be increased when Dersalazine is combined with Clocortolone. Investigational Dichlorvos The risk or severity of adverse effects can be increased when Clocortolone is combined with Dichlorvos. Vet Approved Diclofenac The risk or severity of adverse effects can be increased when Diclofenac is combined with Clocortolone. Approved, Vet Approved Dienestrol The serum concentration of Clocortolone can be increased when it is combined with Dienestrol. Approved, Investigational Diethylstilbestrol The serum concentration of Clocortolone can be increased when it is combined with Diethylstilbestrol. Approved, Investigational Difenpiramide The risk or severity of adverse effects can be increased when Difenpiramide is combined with Clocortolone. Experimental Diflunisal The risk or severity of adverse effects can be increased when Diflunisal is combined with Clocortolone. Approved, Investigational Distigmine The risk or severity of adverse effects can be increased when Clocortolone is combined with Distigmine. Experimental Donepezil The risk or severity of adverse effects can be increased when Clocortolone is combined with Donepezil. Approved Droxicam The risk or severity of adverse effects can be increased when Droxicam is combined with Clocortolone. Withdrawn Duvelisib The risk or severity of adverse effects can be increased when Duvelisib is combined with Clocortolone. Investigational E-6201 The risk or severity of adverse effects can be increased when E-6201 is combined with Clocortolone. Investigational Echothiophate The risk or severity of adverse effects can be increased when Clocortolone is combined with Echothiophate. Approved Edrophonium The risk or severity of adverse effects can be increased when Clocortolone is combined with Edrophonium. Approved Enoxacin The risk or severity of adverse effects can be increased when Clocortolone is combined with Enoxacin. Approved, Investigational Enzalutamide The serum concentration of Clocortolone can be decreased when it is combined with Enzalutamide. Approved Epimestrol The serum concentration of Clocortolone can be increased when it is combined with Epimestrol. Experimental Epirizole The risk or severity of adverse effects can be increased when Epirizole is combined with Clocortolone. Approved Epitizide Clocortolone may increase the hypokalemic activities of Epitizide. Experimental Equol The serum concentration of Clocortolone can be increased when it is combined with Equol. Investigational Estradiol The serum concentration of Clocortolone can be increased when it is combined with Estradiol. Approved, Investigational, Vet Approved Estradiol acetate The serum concentration of Clocortolone can be increased when it is combined with Estradiol acetate. Approved, Investigational, Vet Approved Estradiol cypionate The serum concentration of Clocortolone can be increased when it is combined with Estradiol cypionate. Approved, Investigational, Vet Approved Estradiol valerate The serum concentration of Clocortolone can be increased when it is combined with Estradiol valerate. Approved, Investigational, Vet Approved Estriol The serum concentration of Clocortolone can be increased when it is combined with Estriol. Approved, Investigational, Vet Approved Estrogens, esterified The serum concentration of Clocortolone can be increased when it is combined with Estrogens, esterified. Approved Estrone The serum concentration of Clocortolone can be increased when it is combined with Estrone. Approved Etacrynic acid Clocortolone may increase the hypokalemic activities of Etacrynic acid. Approved, Investigational Etanercept The risk or severity of adverse effects can be increased when Etanercept is combined with Clocortolone. Approved, Investigational Ethenzamide The risk or severity of adverse effects can be increased when Ethenzamide is combined with Clocortolone. Experimental Ethinyl Estradiol The serum concentration of Clocortolone can be increased when it is combined with Ethinyl Estradiol. Approved Etodolac The risk or severity of adverse effects can be increased when Etodolac is combined with Clocortolone. Approved, Investigational, Vet Approved Etofenamate The risk or severity of adverse effects can be increased when Etofenamate is combined with Clocortolone. Approved, Investigational Etoricoxib The risk or severity of adverse effects can be increased when Etoricoxib is combined with Clocortolone. Approved, Investigational Evening primrose oil The risk or severity of adverse effects can be increased when Evening primrose oil is combined with Clocortolone. Investigational, Nutraceutical Exisulind The risk or severity of adverse effects can be increased when Exisulind is combined with Clocortolone. Investigational Felbinac The risk or severity of adverse effects can be increased when Felbinac is combined with Clocortolone. Experimental Fenbufen The risk or severity of adverse effects can be increased when Fenbufen is combined with Clocortolone. Approved Fenoprofen The risk or severity of adverse effects can be increased when Fenoprofen is combined with Clocortolone. Approved Fenthion The risk or severity of adverse effects can be increased when Clocortolone is combined with Fenthion. Vet Approved Fentiazac The risk or severity of adverse effects can be increased when Fentiazac is combined with Clocortolone. Experimental Feprazone The risk or severity of adverse effects can be increased when Feprazone is combined with Clocortolone. Experimental Ferulic acid The risk or severity of adverse effects can be increased when Ferulic acid is combined with Clocortolone. Experimental Fleroxacin The risk or severity of adverse effects can be increased when Clocortolone is combined with Fleroxacin. Approved Floctafenine The risk or severity of adverse effects can be increased when Floctafenine is combined with Clocortolone. Approved, Withdrawn Flumequine The risk or severity of adverse effects can be increased when Clocortolone is combined with Flumequine. Withdrawn Flunixin The risk or severity of adverse effects can be increased when Flunixin is combined with Clocortolone. Vet Approved Flunoxaprofen The risk or severity of adverse effects can be increased when Flunoxaprofen is combined with Clocortolone. Experimental Fluoxymesterone Clocortolone may increase the fluid retaining activities of Fluoxymesterone. Approved, Illicit Flurbiprofen The risk or severity of adverse effects can be increased when Flurbiprofen is combined with Clocortolone. Approved, Investigational Fosaprepitant The serum concentration of Clocortolone can be increased when it is combined with Fosaprepitant. Approved Fosphenytoin The serum concentration of Clocortolone can be decreased when it is combined with Fosphenytoin. Approved, Investigational Furosemide Clocortolone may increase the hypokalemic activities of Furosemide. Approved, Vet Approved G17DT The risk or severity of adverse effects can be increased when Clocortolone is combined with G17DT. Investigational Galantamine The risk or severity of adverse effects can be increased when Clocortolone is combined with Galantamine. Approved Gallamine Triethiodide The risk or severity of adverse effects can be increased when Clocortolone is combined with Gallamine Triethiodide. Approved Garenoxacin The risk or severity of adverse effects can be increased when Clocortolone is combined with Garenoxacin. Investigational Gatifloxacin The risk or severity of adverse effects can be increased when Clocortolone is combined with Gatifloxacin. Approved, Investigational Gemifloxacin The risk or severity of adverse effects can be increased when Clocortolone is combined with Gemifloxacin. Approved, Investigational Genistein The serum concentration of Clocortolone can be increased when it is combined with Genistein. Investigational GI-5005 The risk or severity of adverse effects can be increased when Clocortolone is combined with GI-5005. Investigational GLPG-0492 Clocortolone may increase the fluid retaining activities of GLPG-0492. Investigational Glycerol Phenylbutyrate The therapeutic efficacy of Glycerol Phenylbutyrate can be decreased when used in combination with Clocortolone. Approved Grepafloxacin The risk or severity of adverse effects can be increased when Clocortolone is combined with Grepafloxacin. Approved, Investigational, Withdrawn Guacetisal The risk or severity of adverse effects can be increased when Guacetisal is combined with Clocortolone. Experimental Hemoglobin crosfumaril The risk or severity of adverse effects can be increased when Hemoglobin crosfumaril is combined with Clocortolone. Experimental Hepatitis A Vaccine The risk or severity of adverse effects can be increased when Clocortolone is combined with Hepatitis A Vaccine. Approved Hepatitis B Vaccine (Recombinant) The risk or severity of adverse effects can be increased when Clocortolone is combined with Hepatitis B Vaccine (Recombinant). Approved, Withdrawn Hexestrol The serum concentration of Clocortolone can be increased when it is combined with Hexestrol. Withdrawn Higenamine The risk or severity of adverse effects can be increased when Higenamine is combined with Clocortolone. Investigational Human rabies virus immune globulin The risk or severity of adverse effects can be increased when Clocortolone is combined with Human rabies virus immune globulin. Approved Huperzine A The risk or severity of adverse effects can be increased when Clocortolone is combined with Huperzine A. Approved, Investigational Hyaluronidase The therapeutic efficacy of Hyaluronidase can be decreased when used in combination with Clocortolone. Approved, Investigational Hydrochlorothiazide Clocortolone may increase the hypokalemic activities of Hydrochlorothiazide. Approved, Vet Approved Hydroflumethiazide Clocortolone may increase the hypokalemic activities of Hydroflumethiazide. Approved, Investigational Hydrotalcite The bioavailability of Clocortolone can be decreased when combined with Hydrotalcite. Approved, Experimental, Investigational Ibuprofen The risk or severity of adverse effects can be increased when Ibuprofen is combined with Clocortolone. Approved Ibuproxam The risk or severity of adverse effects can be increased when Ibuproxam is combined with Clocortolone. Withdrawn Icatibant The risk or severity of adverse effects can be increased when Icatibant is combined with Clocortolone. Approved, Investigational Idelalisib The serum concentration of Clocortolone can be increased when it is combined with Idelalisib. Approved Imidazole salicylate The risk or severity of adverse effects can be increased when Imidazole salicylate is combined with Clocortolone. Experimental Indacaterol Indacaterol may increase the hypokalemic activities of Clocortolone. Approved Indapamide Clocortolone may increase the hypokalemic activities of Indapamide. Approved Indinavir The serum concentration of Clocortolone can be increased when it is combined with Indinavir. Approved Indobufen The risk or severity of adverse effects can be increased when Indobufen is combined with Clocortolone. Investigational Indomethacin The risk or severity of adverse effects can be increased when Indomethacin is combined with Clocortolone. Approved, Investigational Indoprofen The risk or severity of adverse effects can be increased when Indoprofen is combined with Clocortolone. Withdrawn INGN 201 The risk or severity of adverse effects can be increased when Clocortolone is combined with INGN 201. Investigational INGN 225 The risk or severity of adverse effects can be increased when Clocortolone is combined with INGN 225. Investigational Ipidacrine The risk or severity of adverse effects can be increased when Clocortolone is combined with Ipidacrine. Experimental Isoflurophate The risk or severity of adverse effects can be increased when Clocortolone is combined with Isoflurophate. Approved, Investigational, Withdrawn Isoniazid The serum concentration of Isoniazid can be decreased when it is combined with Clocortolone. Approved, Investigational Isoxicam The risk or severity of adverse effects can be increased when Isoxicam is combined with Clocortolone. Withdrawn Itraconazole The serum concentration of Clocortolone can be increased when it is combined with Itraconazole. Approved, Investigational Japanese encephalitis virus strain sa 14-14-2 antigen (formaldehyde inactivated) The risk or severity of adverse effects can be increased when Clocortolone is combined with Japanese encephalitis virus strain sa 14-14-2 antigen (formaldehyde inactivated). Approved Kebuzone The risk or severity of adverse effects can be increased when Kebuzone is combined with Clocortolone. Experimental Ketoconazole The serum concentration of Clocortolone can be increased when it is combined with Ketoconazole. Approved, Investigational Ketoprofen The risk or severity of adverse effects can be increased when Ketoprofen is combined with Clocortolone. Approved, Vet Approved Ketorolac The risk or severity of adverse effects can be increased when Ketorolac is combined with Clocortolone. Approved Lacidipine The serum concentration of Lacidipine can be decreased when it is combined with Clocortolone. Approved, Investigational Leflunomide The risk or severity of adverse effects can be increased when Leflunomide is combined with Clocortolone. Approved, Investigational Levofloxacin The risk or severity of adverse effects can be increased when Clocortolone is combined with Levofloxacin. Approved, Investigational Lisofylline The risk or severity of adverse effects can be increased when Lisofylline is combined with Clocortolone. Investigational Lonazolac The risk or severity of adverse effects can be increased when Lonazolac is combined with Clocortolone. Experimental Lopinavir The serum concentration of Clocortolone can be increased when it is combined with Lopinavir. Approved Lornoxicam The risk or severity of adverse effects can be increased when Lornoxicam is combined with Clocortolone. Approved, Investigational Loxoprofen The risk or severity of adverse effects can be increased when Loxoprofen is combined with Clocortolone. Approved, Investigational Lumacaftor The serum concentration of Clocortolone can be decreased when it is combined with Lumacaftor. Approved Lumiracoxib The risk or severity of adverse effects can be increased when Lumiracoxib is combined with Clocortolone. Approved, Investigational Magaldrate The bioavailability of Clocortolone can be decreased when combined with Magaldrate. Approved, Withdrawn Magnesium hydroxide The bioavailability of Clocortolone can be decreased when combined with Magnesium hydroxide. Approved, Investigational Magnesium oxide The bioavailability of Clocortolone can be decreased when combined with Magnesium oxide. Approved Magnesium peroxide The bioavailability of Clocortolone can be decreased when combined with Magnesium peroxide. Experimental Magnesium salicylate The risk or severity of adverse effects can be increased when Magnesium salicylate is combined with Clocortolone. Approved Magnesium silicate The bioavailability of Clocortolone can be decreased when combined with Magnesium silicate. Approved Magnesium Trisilicate The bioavailability of Clocortolone can be decreased when combined with Magnesium Trisilicate. Approved Malathion The risk or severity of adverse effects can be increased when Clocortolone is combined with Malathion. Approved, Investigational Masoprocol The risk or severity of adverse effects can be increased when Masoprocol is combined with Clocortolone. Approved, Investigational Meclofenamic acid The risk or severity of adverse effects can be increased when Meclofenamic acid is combined with Clocortolone. Approved, Vet Approved Mefenamic acid The risk or severity of adverse effects can be increased when Mefenamic acid is combined with Clocortolone. Approved Mefloquine The risk or severity of adverse effects can be increased when Clocortolone is combined with Mefloquine. Approved, Investigational Meloxicam The risk or severity of adverse effects can be increased when Meloxicam is combined with Clocortolone. Approved, Vet Approved Memantine The risk or severity of adverse effects can be increased when Clocortolone is combined with Memantine. Approved, Investigational Mesalazine The risk or severity of adverse effects can be increased when Mesalazine is combined with Clocortolone. Approved Mesterolone Clocortolone may increase the fluid retaining activities of Mesterolone. Experimental Mestranol The serum concentration of Clocortolone can be increased when it is combined with Mestranol. Approved Metamizole The risk or severity of adverse effects can be increased when Metamizole is combined with Clocortolone. Approved, Investigational, Withdrawn Methallenestril The serum concentration of Clocortolone can be increased when it is combined with Methallenestril. Experimental Methanesulfonyl Fluoride The risk or severity of adverse effects can be increased when Clocortolone is combined with Methanesulfonyl Fluoride. Investigational Methyclothiazide Clocortolone may increase the hypokalemic activities of Methyclothiazide. Approved Methyl salicylate The risk or severity of adverse effects can be increased when Methyl salicylate is combined with Clocortolone. Approved, Vet Approved Methyltestosterone Clocortolone may increase the fluid retaining activities of Methyltestosterone. Approved Metoclopramide The risk or severity of adverse effects can be increased when Clocortolone is combined with Metoclopramide. Approved, Investigational Metolazone Clocortolone may increase the hypokalemic activities of Metolazone. Approved Mifepristone The therapeutic efficacy of Clocortolone can be decreased when used in combination with Mifepristone. Approved, Investigational Minaprine The risk or severity of adverse effects can be increased when Clocortolone is combined with Minaprine. Approved Mitotane The serum concentration of Clocortolone can be decreased when it is combined with Mitotane. Approved Mivacurium Mivacurium may increase the adverse neuromuscular activities of Clocortolone. Approved Mizoribine The risk or severity of adverse effects can be increased when Mizoribine is combined with Clocortolone. Investigational Mofebutazone The risk or severity of adverse effects can be increased when Mofebutazone is combined with Clocortolone. Experimental Moxestrol The serum concentration of Clocortolone can be increased when it is combined with Moxestrol. Experimental Mycophenolate mofetil The risk or severity of adverse effects can be increased when Mycophenolate mofetil is combined with Clocortolone. Approved, Investigational Mycophenolic acid The risk or severity of adverse effects can be increased when Mycophenolic acid is combined with Clocortolone. Approved Nabumetone The risk or severity of adverse effects can be increased when Nabumetone is combined with Clocortolone. Approved Nafamostat The risk or severity of adverse effects can be increased when Nafamostat is combined with Clocortolone. Approved, Investigational Naftifine The risk or severity of adverse effects can be increased when Naftifine is combined with Clocortolone. Approved Nalidixic Acid The risk or severity of adverse effects can be increased when Clocortolone is combined with Nalidixic Acid. Approved, Investigational Nandrolone Clocortolone may increase the fluid retaining activities of Nandrolone. Experimental, Investigational Nandrolone decanoate Clocortolone may increase the fluid retaining activities of Nandrolone decanoate. Approved, Illicit Naproxen The risk or severity of adverse effects can be increased when Naproxen is combined with Clocortolone. Approved, Vet Approved Nefazodone The serum concentration of Clocortolone can be increased when it is combined with Nefazodone. Approved, Withdrawn Nelfinavir The serum concentration of Clocortolone can be increased when it is combined with Nelfinavir. Approved Nemonoxacin The risk or severity of adverse effects can be increased when Clocortolone is combined with Nemonoxacin. Investigational Neostigmine The risk or severity of adverse effects can be increased when Clocortolone is combined with Neostigmine. Approved, Vet Approved Nepafenac The risk or severity of adverse effects can be increased when Nepafenac is combined with Clocortolone. Approved, Investigational Nevirapine The serum concentration of Clocortolone can be decreased when it is combined with Nevirapine. Approved Nicorandil The risk or severity of adverse effects can be increased when Clocortolone is combined with Nicorandil. Approved, Investigational Nifenazone The risk or severity of adverse effects can be increased when Nifenazone is combined with Clocortolone. Experimental Niflumic Acid The risk or severity of adverse effects can be increased when Niflumic Acid is combined with Clocortolone. Approved Nimesulide The risk or severity of adverse effects can be increased when Nimesulide is combined with Clocortolone. Approved, Investigational, Withdrawn Nitroaspirin The risk or severity of adverse effects can be increased when Nitroaspirin is combined with Clocortolone. Investigational Norfloxacin The risk or severity of adverse effects can be increased when Clocortolone is combined with Norfloxacin. Approved Olopatadine The risk or severity of adverse effects can be increased when Olopatadine is combined with Clocortolone. Approved Olsalazine The risk or severity of adverse effects can be increased when Olsalazine is combined with Clocortolone. Approved Orgotein The risk or severity of adverse effects can be increased when Orgotein is combined with Clocortolone. Vet Approved Oxandrolone Clocortolone may increase the fluid retaining activities of Oxandrolone. Approved, Investigational Oxaprozin The risk or severity of adverse effects can be increased when Oxaprozin is combined with Clocortolone. Approved Oxolinic acid The risk or severity of adverse effects can be increased when Clocortolone is combined with Oxolinic acid. Experimental Oxymetholone Clocortolone may increase the fluid retaining activities of Oxymetholone. Approved, Illicit Oxyphenbutazone The risk or severity of adverse effects can be increased when Oxyphenbutazone is combined with Clocortolone. Approved, Withdrawn Paraoxon The risk or severity of adverse effects can be increased when Clocortolone is combined with Paraoxon. Experimental Parecoxib The risk or severity of adverse effects can be increased when Parecoxib is combined with Clocortolone. Approved Parthenolide The risk or severity of adverse effects can be increased when Parthenolide is combined with Clocortolone. Approved, Investigational Pazufloxacin The risk or severity of adverse effects can be increased when Clocortolone is combined with Pazufloxacin. Investigational Pefloxacin The risk or severity of adverse effects can be increased when Clocortolone is combined with Pefloxacin. Approved Pentobarbital The serum concentration of Clocortolone can be decreased when it is combined with Pentobarbital. Approved, Investigational, Vet Approved Phenobarbital The serum concentration of Clocortolone can be decreased when it is combined with Phenobarbital. Approved, Investigational Phenyl aminosalicylate The risk or severity of adverse effects can be increased when Phenyl aminosalicylate is combined with Clocortolone. Approved Phenylacetic acid The therapeutic efficacy of Phenylacetic acid can be decreased when used in combination with Clocortolone. Approved Phenylbutazone The risk or severity of adverse effects can be increased when Phenylbutazone is combined with Clocortolone. Approved, Vet Approved Phenylbutyric acid The therapeutic efficacy of Phenylbutyric acid can be decreased when used in combination with Clocortolone. Approved, Investigational Phenytoin The serum concentration of Clocortolone can be decreased when it is combined with Phenytoin. Approved, Vet Approved Physostigmine The risk or severity of adverse effects can be increased when Clocortolone is combined with Physostigmine. Approved, Investigational Pimecrolimus The risk or severity of adverse effects can be increased when Pimecrolimus is combined with Clocortolone. Approved, Investigational Pipemidic acid The risk or severity of adverse effects can be increased when Clocortolone is combined with Pipemidic acid. Experimental Piretanide Clocortolone may increase the hypokalemic activities of Piretanide. Approved Pirfenidone The risk or severity of adverse effects can be increased when Pirfenidone is combined with Clocortolone. Approved, Investigational Piromidic acid The risk or severity of adverse effects can be increased when Clocortolone is combined with Piromidic acid. Experimental Piroxicam The risk or severity of adverse effects can be increased when Piroxicam is combined with Clocortolone. Approved, Investigational Pirprofen The risk or severity of adverse effects can be increased when Pirprofen is combined with Clocortolone. Experimental Polyestradiol phosphate The serum concentration of Clocortolone can be increased when it is combined with Polyestradiol phosphate. Approved Polythiazide Clocortolone may increase the hypokalemic activities of Polythiazide. Approved Posaconazole The serum concentration of Clocortolone can be increased when it is combined with Posaconazole. Approved, Investigational, Vet Approved Pranoprofen The risk or severity of adverse effects can be increased when Pranoprofen is combined with Clocortolone. Experimental, Investigational Primidone The serum concentration of Clocortolone can be decreased when it is combined with Primidone. Approved, Vet Approved Proglumetacin The risk or severity of adverse effects can be increased when Proglumetacin is combined with Clocortolone. Experimental Promestriene The serum concentration of Clocortolone can be increased when it is combined with Promestriene. Investigational Propacetamol The risk or severity of adverse effects can be increased when Propacetamol is combined with Clocortolone. Approved, Investigational Propyphenazone The risk or severity of adverse effects can be increased when Propyphenazone is combined with Clocortolone. Experimental Proquazone The risk or severity of adverse effects can be increased when Proquazone is combined with Clocortolone. Experimental Prulifloxacin The risk or severity of adverse effects can be increased when Clocortolone is combined with Prulifloxacin. Investigational PTC299 The risk or severity of adverse effects can be increased when PTC299 is combined with Clocortolone. Investigational Pyridostigmine The risk or severity of adverse effects can be increased when Clocortolone is combined with Pyridostigmine. Approved, Investigational Quinestrol The serum concentration of Clocortolone can be increased when it is combined with Quinestrol. Approved Quinethazone Clocortolone may increase the hypokalemic activities of Quinethazone. Approved Rabies virus inactivated antigen, A The risk or severity of adverse effects can be increased when Clocortolone is combined with Rabies virus inactivated antigen, A. Approved, Investigational Rapacuronium Rapacuronium may increase the adverse neuromuscular activities of Clocortolone. Withdrawn Resveratrol The risk or severity of adverse effects can be increased when Resveratrol is combined with Clocortolone. Approved, Experimental, Investigational Rifabutin The serum concentration of Clocortolone can be decreased when it is combined with Rifabutin. Approved, Investigational Rifampicin The serum concentration of Clocortolone can be decreased when it is combined with Rifampicin. Approved Rifapentine The serum concentration of Clocortolone can be decreased when it is combined with Rifapentine. Approved, Investigational Rindopepimut The risk or severity of adverse effects can be increased when Clocortolone is combined with Rindopepimut. Investigational Rivastigmine The risk or severity of adverse effects can be increased when Clocortolone is combined with Rivastigmine. Approved, Investigational Rofecoxib The risk or severity of adverse effects can be increased when Rofecoxib is combined with Clocortolone. Approved, Investigational, Withdrawn Rosoxacin The risk or severity of adverse effects can be increased when Clocortolone is combined with Rosoxacin. Approved, Investigational Rotavirus Vaccine The risk or severity of adverse effects can be increased when Clocortolone is combined with Rotavirus Vaccine. Approved Rubella virus vaccine The risk or severity of adverse effects can be increased when Clocortolone is combined with Rubella virus vaccine. Approved, Investigational Rufloxacin The risk or severity of adverse effects can be increased when Clocortolone is combined with Rufloxacin. Experimental Salicylamide The risk or severity of adverse effects can be increased when Salicylamide is combined with Clocortolone. Approved Salicylic acid The risk or severity of adverse effects can be increased when Salicylic acid is combined with Clocortolone. Approved, Investigational, Vet Approved Salmonella typhi ty2 vi polysaccharide antigen The risk or severity of adverse effects can be increased when Clocortolone is combined with Salmonella typhi ty2 vi polysaccharide antigen. Approved Salmonella typhi ty21a live antigen The risk or severity of adverse effects can be increased when Clocortolone is combined with Salmonella typhi ty21a live antigen. Approved Salsalate The risk or severity of adverse effects can be increased when Salsalate is combined with Clocortolone. Approved Saquinavir The serum concentration of Clocortolone can be increased when it is combined with Saquinavir. Approved, Investigational Secoisolariciresinol The serum concentration of Clocortolone can be increased when it is combined with Secoisolariciresinol. Investigational Semapimod The risk or severity of adverse effects can be increased when Semapimod is combined with Clocortolone. Investigational Seratrodast The risk or severity of adverse effects can be increased when Seratrodast is combined with Clocortolone. Approved Serrapeptase The risk or severity of adverse effects can be increased when Serrapeptase is combined with Clocortolone. Investigational Sitafloxacin The risk or severity of adverse effects can be increased when Clocortolone is combined with Sitafloxacin. Experimental, Investigational Sodium bicarbonate The bioavailability of Clocortolone can be decreased when combined with Sodium bicarbonate. Approved Sparfloxacin The risk or severity of adverse effects can be increased when Clocortolone is combined with Sparfloxacin. Approved, Investigational SRP 299 The risk or severity of adverse effects can be increased when Clocortolone is combined with SRP 299. Investigational SRT501 The risk or severity of adverse effects can be increased when SRT501 is combined with Clocortolone. Investigational St. John's Wort The serum concentration of Clocortolone can be decreased when it is combined with St. John's Wort. Approved, Investigational, Nutraceutical Stanolone Clocortolone may increase the fluid retaining activities of Stanolone. Illicit, Investigational Stanozolol Clocortolone may increase the fluid retaining activities of Stanozolol. Approved, Vet Approved Stiripentol The serum concentration of Clocortolone can be increased when it is combined with Stiripentol. Approved Sulfasalazine The risk or severity of adverse effects can be increased when Sulfasalazine is combined with Clocortolone. Approved Sulindac The risk or severity of adverse effects can be increased when Sulindac is combined with Clocortolone. Approved, Investigational Suprofen The risk or severity of adverse effects can be increased when Suprofen is combined with Clocortolone. Approved, Withdrawn Suxibuzone The risk or severity of adverse effects can be increased when Suxibuzone is combined with Clocortolone. Experimental Synthetic Conjugated Estrogens, A The serum concentration of Clocortolone can be increased when it is combined with Synthetic Conjugated Estrogens, A. Approved Synthetic Conjugated Estrogens, B The serum concentration of Clocortolone can be increased when it is combined with Synthetic Conjugated Estrogens, B. Approved Tacrine The risk or severity of adverse effects can be increased when Clocortolone is combined with Tacrine. Investigational, Withdrawn Tarenflurbil The risk or severity of adverse effects can be increased when Tarenflurbil is combined with Clocortolone. Investigational Tecemotide The risk or severity of adverse effects can be increased when Clocortolone is combined with Tecemotide. Investigational Telaprevir The serum concentration of Telaprevir can be decreased when it is combined with Clocortolone. Approved, Withdrawn Telithromycin The serum concentration of Clocortolone can be increased when it is combined with Telithromycin. Approved Temafloxacin The risk or severity of adverse effects can be increased when Clocortolone is combined with Temafloxacin. Withdrawn Tenidap The risk or severity of adverse effects can be increased when Tenidap is combined with Clocortolone. Experimental Tenoxicam The risk or severity of adverse effects can be increased when Tenoxicam is combined with Clocortolone. Approved Tepoxalin The risk or severity of adverse effects can be increased when Tepoxalin is combined with Clocortolone. Vet Approved Teriflunomide The risk or severity of adverse effects can be increased when Teriflunomide is combined with Clocortolone. Approved Testosterone Clocortolone may increase the fluid retaining activities of Testosterone. Approved, Investigational Testosterone cypionate The risk or severity of edema formation can be increased when Testosterone cypionate is combined with Clocortolone. Approved Testosterone enanthate The risk or severity of edema formation can be increased when Testosterone enanthate is combined with Clocortolone. Approved Testosterone propionate Clocortolone may increase the fluid retaining activities of Testosterone propionate. Approved, Investigational, Vet Approved, Withdrawn Testosterone undecanoate The risk or severity of fluid retention can be increased when Testosterone undecanoate is combined with Clocortolone. Approved, Investigational TG4010 The risk or severity of adverse effects can be increased when Clocortolone is combined with TG4010. Investigational Tiaprofenic acid The risk or severity of adverse effects can be increased when Tiaprofenic acid is combined with Clocortolone. Approved Tibolone The serum concentration of Clocortolone can be increased when it is combined with Tibolone. Approved, Investigational Tinoridine The risk or severity of adverse effects can be increased when Tinoridine is combined with Clocortolone. Investigational Tolfenamic Acid The risk or severity of adverse effects can be increased when Tolfenamic Acid is combined with Clocortolone. Approved, Investigational Tolmetin The risk or severity of adverse effects can be increased when Tolmetin is combined with Clocortolone. Approved Torasemide Clocortolone may increase the hypokalemic activities of Torasemide. Approved Tranilast The risk or severity of adverse effects can be increased when Tranilast is combined with Clocortolone. Approved, Investigational Tribenoside The risk or severity of adverse effects can be increased when Tribenoside is combined with Clocortolone. Experimental Trichlorfon The risk or severity of adverse effects can be increased when Clocortolone is combined with Trichlorfon. Vet Approved Trichlormethiazide Clocortolone may increase the hypokalemic activities of Trichlormethiazide. Approved, Vet Approved Triptolide The risk or severity of adverse effects can be increased when Triptolide is combined with Clocortolone. Investigational Trolamine salicylate The risk or severity of adverse effects can be increased when Trolamine salicylate is combined with Clocortolone. Approved Tromethamine The bioavailability of Clocortolone can be decreased when combined with Tromethamine. Approved Trovafloxacin The risk or severity of adverse effects can be increased when Clocortolone is combined with Trovafloxacin. Approved, Investigational, Withdrawn Tubocurarine The risk or severity of adverse effects can be increased when Clocortolone is combined with Tubocurarine. Approved Tyrothricin The risk or severity of adverse effects can be increased when Clocortolone is combined with Tyrothricin. Approved Valdecoxib The risk or severity of adverse effects can be increased when Valdecoxib is combined with Clocortolone. Approved, Investigational, Withdrawn Varicella Zoster Vaccine (Live/Attenuated) The risk or severity of adverse effects can be increased when Clocortolone is combined with Varicella Zoster Vaccine (Live/Attenuated). Approved Voriconazole The serum concentration of Clocortolone can be increased when it is combined with Voriconazole. Approved, Investigational Warfarin Clocortolone may increase the anticoagulant activities of Warfarin. Approved Yellow Fever Vaccine The risk or severity of adverse effects can be increased when Clocortolone is combined with Yellow Fever Vaccine. Approved, Investigational Zaltoprofen The risk or severity of adverse effects can be increased when Zaltoprofen is combined with Clocortolone. Approved, Investigational Zeranol The serum concentration of Clocortolone can be increased when it is combined with Zeranol. Vet Approved Zileuton The risk or severity of adverse effects can be increased when Zileuton is combined with Clocortolone. Approved, Investigational, Withdrawn Zomepirac The risk or severity of adverse effects can be increased when Zomepirac is combined with Clocortolone. Withdrawn - Food Interactions
- Not Available
References
- General References
- Not Available
- External Links
- Human Metabolome Database
- HMDB0014976
- KEGG Drug
- D07719
- PubChem Compound
- 5311052
- PubChem Substance
- 46505290
- ChemSpider
- 4470589
- ChEBI
- 59582
- Therapeutic Targets Database
- DAP001190
- PharmGKB
- PA164744013
- RxList
- RxList Drug Page
- Drugs.com
- Drugs.com Drug Page
- Wikipedia
- Clocortolone
- ATC Codes
- D07AB21 — Clocortolone
- FDA label
- Download (167 KB)
Clinical Trials
Pharmacoeconomics
- Manufacturers
- Dow pharmaceutical sciences inc
- Packagers
- Coria Laboratories
- DPT Laboratories Ltd.
- Valeant Ltd.
- Dosage forms
Form Route Strength Cream Topical .001 g/g - Prices
Unit description Cost Unit Cloderm 0.1% Cream 45 gm Tube 140.98USD tube Cloderm 0.1% cream 3.64USD g DrugBank does not sell nor buy drugs. Pricing information is supplied for informational purposes only.- Patents
- Not Available
Properties
- State
- Solid
- Experimental Properties
Property Value Source logP 3.8 Not Available - Predicted Properties
Property Value Source Water Solubility 0.015 mg/mL ALOGPS logP 2.73 ALOGPS logP 2.47 ChemAxon logS -4.4 ALOGPS pKa (Strongest Acidic) 13.53 ChemAxon pKa (Strongest Basic) -3.3 ChemAxon Physiological Charge 0 ChemAxon Hydrogen Acceptor Count 4 ChemAxon Hydrogen Donor Count 2 ChemAxon Polar Surface Area 74.6 Å2 ChemAxon Rotatable Bond Count 2 ChemAxon Refractivity 105.74 m3·mol-1 ChemAxon Polarizability 41.8 Å3 ChemAxon Number of Rings 4 ChemAxon Bioavailability 1 ChemAxon Rule of Five Yes ChemAxon Ghose Filter Yes ChemAxon Veber's Rule No ChemAxon MDDR-like Rule No ChemAxon - Predicted ADMET features
Property Value Probability Human Intestinal Absorption + 1.0 Blood Brain Barrier + 0.9737 Caco-2 permeable + 0.8054 P-glycoprotein substrate Substrate 0.7404 P-glycoprotein inhibitor I Non-inhibitor 0.7095 P-glycoprotein inhibitor II Non-inhibitor 0.8814 Renal organic cation transporter Non-inhibitor 0.8141 CYP450 2C9 substrate Non-substrate 0.8412 CYP450 2D6 substrate Non-substrate 0.8977 CYP450 3A4 substrate Substrate 0.7374 CYP450 1A2 substrate Non-inhibitor 0.9164 CYP450 2C9 inhibitor Non-inhibitor 0.9119 CYP450 2D6 inhibitor Non-inhibitor 0.9061 CYP450 2C19 inhibitor Non-inhibitor 0.9182 CYP450 3A4 inhibitor Inhibitor 0.6251 CYP450 inhibitory promiscuity Low CYP Inhibitory Promiscuity 0.857 Ames test Non AMES toxic 0.8537 Carcinogenicity Non-carcinogens 0.8855 Biodegradation Not ready biodegradable 1.0 Rat acute toxicity 1.9732 LD50, mol/kg Not applicable hERG inhibition (predictor I) Weak inhibitor 0.9619 hERG inhibition (predictor II) Non-inhibitor 0.5411
Spectra
- Mass Spec (NIST)
- Not Available
- Spectra
Spectrum Spectrum Type Splash Key Predicted GC-MS Spectrum - GC-MS Predicted GC-MS Not Available Predicted MS/MS Spectrum - 10V, Positive (Annotated) Predicted LC-MS/MS Not Available Predicted MS/MS Spectrum - 20V, Positive (Annotated) Predicted LC-MS/MS Not Available Predicted MS/MS Spectrum - 40V, Positive (Annotated) Predicted LC-MS/MS Not Available Predicted MS/MS Spectrum - 10V, Negative (Annotated) Predicted LC-MS/MS Not Available Predicted MS/MS Spectrum - 20V, Negative (Annotated) Predicted LC-MS/MS Not Available Predicted MS/MS Spectrum - 40V, Negative (Annotated) Predicted LC-MS/MS Not Available
Taxonomy
- Description
- This compound belongs to the class of organic compounds known as 21-hydroxysteroids. These are steroids carrying a hydroxyl group at the 21-position of the steroid backbone.
- Kingdom
- Organic compounds
- Super Class
- Lipids and lipid-like molecules
- Class
- Steroids and steroid derivatives
- Sub Class
- Hydroxysteroids
- Direct Parent
- 21-hydroxysteroids
- Alternative Parents
- Gluco/mineralocorticoids, progestogins and derivatives / 20-oxosteroids / 11-beta-hydroxysteroids / 3-oxo delta-1,4-steroids / Halogenated steroids / Delta-1,4-steroids / Alpha-hydroxy ketones / Secondary alcohols / Chlorohydrins / Cyclic ketones show 8 more
- Substituents
- 21-hydroxysteroid / Progestogin-skeleton / 20-oxosteroid / Pregnane-skeleton / 6-halo-steroid / Halo-steroid / 3-oxo-delta-1,4-steroid / 9-halo-steroid / 3-oxosteroid / Oxosteroid show 24 more
- Molecular Framework
- Aliphatic homopolycyclic compounds
- External Descriptors
- 11beta-hydroxy steroid, glucocorticoid, 20-oxo steroid, fluorinated steroid, 3-oxo-Delta(1),Delta(4)-steroid, chlorinated steroid, 21-hydroxy steroid (CHEBI:59582)
Targets
- Kind
- Protein
- Organism
- Human
- Pharmacological action
- Yes
- Actions
- Agonist
- General Function
- Zinc ion binding
- Specific Function
- Receptor for glucocorticoids (GC). Has a dual mode of action: as a transcription factor that binds to glucocorticoid response elements (GRE), both for nuclear and mitochondrial DNA, and as a modula...
- Gene Name
- NR3C1
- Uniprot ID
- P04150
- Uniprot Name
- Glucocorticoid receptor
- Molecular Weight
- 85658.57 Da
References
- Ali A, Balkovec JM, Greenlee M, Hammond ML, Rouen G, Taylor G, Einstein M, Ge L, Harris G, Kelly TM, Mazur P, Pandit S, Santoro J, Sitlani A, Wang C, Williamson J, Forrest MJ, Carballo-Jane E, Luell S, Lowitz K, Visco D: Discovery of betamethasone 17alpha-carbamates as dissociated glucocorticoid receptor modulators in the rat. Bioorg Med Chem. 2008 Aug 15;16(16):7535-42. doi: 10.1016/j.bmc.2008.07.037. Epub 2008 Jul 20. [PubMed:18691892]
- Buchwald P: Glucocorticoid receptor binding: a biphasic dependence on molecular size as revealed by the bilinear LinBiExp model. Steroids. 2008 Feb;73(2):193-208. Epub 2007 Oct 11. [PubMed:18022656]
- Tanigawa K, Nagase H, Ohmori K, Tanaka K, Miyake H, Kiniwa M, Ikizawa K: Species-specific differences in the glucocorticoid receptor transactivation function upon binding with betamethasone-esters. Int Immunopharmacol. 2002 Jun;2(7):941-50. [PubMed:12188035]
Drug created on June 13, 2005 07:24 / Updated on May 02, 2018 01:34